Nadide liposomal - Innomedica
Alternative Names: Liposomal NAD+; NADLatest Information Update: 08 Jan 2022
Price :
$50 *
At a glance
- Originator InnoMedica
- Class Antiparkinsonians; Coenzymes
- Mechanism of Action Tyrosine hydroxylase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Metabolic disorders; Multiple sclerosis
Most Recent Events
- 28 Jun 2021 No recent reports of development identified for preclinical development in Metabolic-disorders in Switzerland (Liposomal)
- 28 Jun 2021 No recent reports of development identified for preclinical development in Multiple-sclerosis in Switzerland (Liposomal)
- 16 May 2017 Chemical structure information added